|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ϸ�������� |
|
Ƥ���� |
|
���� |
| ��������������� | |
|
�Խ��� |
|
��ǧ�� |
| PubMed | |
|
Article by |
|
Article by |
ϸ�������Ʒ���Ƥ���Ƶ�Ӧ�ü���չ
�Խ���, ��ǧ��
�й�ҽѧ��ѧԺ�й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ� 210042
ϸ����������ϸ�����ڵľ���������Ե�С���ӵ������ʵ�ͳ��,��������༲���ķ�������չ��������Ҫ����.��������ϸ�����ӵ���ʶ�Ѳ�������ʵ�����еIJ�������ѧ�о�,ϸ�������Ʒ����������Ƹ�Ⱦ��Ƥ������������֢��Ƥ����������������Ƥ�����������Ȳ�ȡ��һ����Ч.
[2] Dinsmore W,Jordan J,O��Mahony C,et al.Recombinant human interferon-beta in the treatment of condylomata acuminata.Int J STD AIDS,1997,8(10):622-628.
[3] Borrego L,Castro I,Frances A,et al.Treatment of acyclovir-resistant perianal herpetic ulceration with intramuscular interferon alfa.Arch Dermatol,1996,132(10):1157-1158.
[4] Rossi S,Whitfeld M,Berger TG.The treatment of acyclovir-resistant herpes zoster with trifluorothymidine and interferon alfa.Arch Dermatol,1995,131(1):24-26.
[5] Thomas P.IL-4 induced immune deviation as therapy of psoriasis.Arch Dermatol Res,2001,293(1-2):39.
[6] Asadullah K,Docke WD,Ebeling M,et al.Interleukin 10 treatment of psoriasis:clinical results of a phase 2 trial.Arch Dermatol,1999,135(2):187-192.
[7] Trepicchio WL,Ozawa M,Walters IB,et al.Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions.J Clin Invest,1999,104(11):1527-1537.
[8] Schopf RE,Aust H,Knop J.Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha,infliximab.J Am Acad Dennatol,2002,46(6):886-891.
[9] Iyer S,Yamauchi P,Lowe NJ.Etanercept for severe psoriasis and psoriatic arthritis:observations on combination therapy.Br J Dermatol,2002,146(1):118-121.
[10] Hanifin JM,Schneider LC,Leung DY,et al.Recombinant interferon gamma therapy for atopic dermatitis.J Am Acad Dermatol,1993,28(2 Pt 1):189-197.
[11] Alpsoy E,Durusoy C,Yilmaz E,et al.Interferon alfa-2a in the treatment of Behcet disease:a randomized placebo-controlled and double-blind study.Arch Dermatol,2002,138(4):467-471.
[12] Zouboulis CC,Orfanos CE.Treatment of Adamantiades-Behcet disease with systemic interferon alfa.Arch Dermatol,1998,134(8):1010-1016.
[13] Kirkwood JM,Strawderman MH,Ernstoff MS,et al.Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma:the Eastern Cooperative Oncology Group Trial EST 1684.J Clin Oncol,1996,14(1):7-17.
[14] Rosenberg SA,Yang JC,Topalian SL,et al.Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.JAMA,1994,271(12):907-913.
[15] Philip PA,Flaherty L.Treatment of malignant melanoma with interleukin-2.Semin Oncol,1997,24(1 Suppl 4):S32-S38.
[16] Kang WK,Park C,Yoon HL,et al.Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts:outcome of a phase I study.Hum Gene Ther,2001,12(6):671-684.
[17] Spitler LE,Grossbard ML,Ernstoff MS,et al.Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.J C lin Oncol,2000,18(8):1614-1621.
[18] Siegel RS,Pandolfino T,Guitart J,et al.Primary cutaneous T-cell lymphoma:review and current concepts.J Clin Oncol,2000,18(15):2908-2925.
[19] Jumbou O,N'Guyen JM,Tessier MH,et al.Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa.Br J Dermatol,1999,140(3):427-431.
[20] Rook AH,Wood GS,Yoo EK,et al.Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.Blood,1999,94(3):902-908.
[21] Marolleau JP,Baccard M,Flageul B,et al.High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.Arch Dermatol,1995,131(5):574-579.
[22] Costa da Cunha CS,Lebbe C,Rybojad M,et al.Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b.Arch Dermatol,1996,132(3):285-290.
[23] Pfrommer C,Tebbe B,Tidona CA,et al.Progressive HHV-8-positive classic Kaposi's sarcoma:rapid response to interferon alpha-2a but persistence of HHV-8 DNA sequences in lesional skin.Br J Dermatol,1998,139(3):516-519.
[24] Tamayo L,Ortiz DM,Orozco-Covarrubias L,et al.Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas.Arch Dermatol,1997,133(12):1567-1571.
[25] Gaches F,Blanc AS,Coaret B,et al.Digital necroses and Sharp's syndrome:the success of topical application of granulocyte/macrophage-colony stimulating factor in promoting healing after amputation of three toes.Br J Dermatol,1998,138(3):550-551.